Clonal diversity revealed by morphoproteomic and copy number profiles of single prostate cancer cells at diagnosis

Convergent Science Physical Oncology
Paymaneh D MalihiPeter Kuhn

Abstract

Tumor heterogeneity is prevalent in both treatment-naïve and end-stage metastatic castration-resistant prostate cancer (PCa), and may contribute to the broad range of clinical presentation, treatment response, and disease progression. To characterize molecular heterogeneity associated with de novo metastatic PCa, multiplatform single cell profiling was performed using high definition single cell analysis (HD-SCA). HD-SCA enabled morphoproteomic and morphogenomic profiling of single cells from touch preparations of tissue cores (prostate and bone marrow biopsies) as well as liquid samples (peripheral blood and bone marrow aspirate). Morphology, nuclear features, copy number alterations, and protein expression were analyzed. Tumor cells isolated from prostate tissue touch preparation (PTTP) and bone marrow touch preparation (BMTP) as well as metastatic tumor cells (MTCs) isolated from bone marrow aspirate were characterized by morphology and cytokeratin expression. Although peripheral blood was examined, circulating tumor cells were not definitively observed. Targeted proteomics of PTTP, BMTP, and MTCs revealed cell lineage and luminal prostate epithelial differentiation associated with PCa, including co-expression of EpCAM, PSA,...Continue Reading

References

Nov 23, 2000·Nature·R A DePinho
Jul 12, 2002·Drug Discovery Today·Burkhard Haefner
Jan 7, 2004·Nature Reviews. Molecular Cell Biology·Zuzana Storchova, David Pellman
Apr 6, 2004·Journal of Clinical Laboratory Analysis·Roger S RileyJonathan M Ben-Ezra
Sep 6, 2005·Cancer Research·Irina U AgoulnikNancy L Weigel
Feb 9, 2006·Biosensors & Bioelectronics·H Ben HsiehJorge Nieva
Dec 26, 2006·Human Pathology·Dena MarrinucciPeter Kuhn
Jan 22, 2009·Genes, Chromosomes & Cancer·Francesca DemichelisMark A Rubin
Mar 25, 2009·Nature Reviews. Cancer·Christoph A Klein
Jan 30, 2010·Journal of Oncology·Dena MarrinucciPeter Kuhn
Mar 27, 2010·Bioinformatics·Grégoire PauWolfgang Huber
Jun 29, 2010·Cancer Cell·Barry S TaylorWilliam L Gerald
Mar 15, 2011·Nature·Nicholas NavinMichael Wigler
Feb 7, 2012·Physical Biology·Dena MarrinucciPeter Kuhn
May 5, 2012·Nature Protocols·Timour BaslanJames Hicks
Sep 14, 2013·Science·Vicki PlaksZena Werb
Mar 4, 2014·Nature Methods·Charlotte GiesenBernd Bodenmiller
Aug 16, 2014·Current Opinion in Biotechnology·Serena Di Palma, Bernd Bodenmiller
Oct 29, 2015·The New England Journal of Medicine·Joaquin MateoJohann S de Bono
Oct 6, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anders CarlssonAmado J Zurita
May 20, 2017·Oncology Letters·Yanling Liu
Jun 6, 2017·The New England Journal of Medicine·Nicholas D JamesUNKNOWN STAMPEDE Investigators
Mar 25, 2019·Convergent Science Physical Oncology·Erik GerdtssonPeter Kuhn

❮ Previous
Next ❯

Citations

Aug 10, 2018·BioTechniques·Francesca Lake
Dec 5, 2019·Frontiers in Immunology·Heeva BaharlouEllis Patrick
May 31, 2020·Cancers·Drahomír KolenčíkPeter Kuhn
Jan 9, 2019·Cold Spring Harbor Perspectives in Medicine·Naishitha AnaparthyJames Hicks
Jul 10, 2019·Genome Biology·Rishvanth K PrabakarAndrew D Smith

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.